[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606214":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":24,"interventions":45,"overallOfficials":54,"centralContacts":59,"locations":65,"responsibleParty":83,"collaborators":13,"id":85,"slug":13,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":13,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":13,"studyType":98,"phases":99,"briefSummary":102,"conditions":103,"keywords":13,"overallStatus":68,"whyStopped":13,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Sirius Therapeutics Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of treatment-emergent adverse events (TEAEs)","A summary of TEAE to evaluate the safety and tolerability of SRSD216","1 year",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"TRIPLE",[21,22,23],"CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[25,31,36,40],{"label":26,"type":27,"description":28,"interventionNames":29},"SRSD216 injection (Part 1)","EXPERIMENTAL","SRSD216 administered SC. in subjects of Part 1",[30],"Drug: SRSD216 injection",{"label":32,"type":27,"description":33,"interventionNames":34},"SRSD216 injection (Part 2)","SRSD216 administered SC. in subjects of Part 2",[30,35],"Drug: Placebo",{"label":37,"type":27,"description":38,"interventionNames":39},"0.9% Sodium Chloride (Part 1)","Placbo administered SC. in subjects of Part 1",[35],{"label":41,"type":42,"description":43,"interventionNames":44},"0.9% Sodium Chloride (Part 2)","PLACEBO_COMPARATOR","Placbo administered SC. in subjects of Part 2",[30,35],[46,51],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":13},"DRUG","SRSD216 injection","Administered SC.",[41,26,32],{"type":47,"name":52,"description":49,"armGroupLabels":53,"otherNames":13},"Placebo",[37,41,32],[55],{"name":56,"affiliation":57,"role":58},"Medical Director, MD","Sirius Therapeutics","STUDY_DIRECTOR",[60],{"name":61,"role":62,"phone":63,"phoneExt":13,"email":64},"Medical Director","CONTACT","+86 21 61207756","medical@siriusrna.com",[66],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"Site 01","RECRUITING","Beijing","Beijing Municipality","100000","China","CN",{"type":75,"coordinates":76},"Point",[77,78],116.39723,39.9075,{"lat":78,"lon":77},[81],{"name":82,"role":62,"phone":63,"phoneExt":13,"email":64},"Investigator",{"type":84,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100606214",false,"NCT07172646","A Study of SRSD216 in Patients With Elevated Lipoprotein (a)","A Phase I\u002FII, Randomized, Double Blind, Placebo Controlled, Dose-Escalation and -Expansion Study to Evaluate the Safety, Tolerability, PK, and PD of Subcutaneously Administered SRSD216 in Patients With Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions;\n* Males or females, of any race;\n* Body mass index (BMI) between 18.0 and 40.0 kg\u002Fm2, inclusive;\n* Male subjects are not allowed to donate sperm, and female subjects are not allowed to donate eggs from the time the ICF is signed until at least 3 months after the last follow-up.\n\nExclusion Criteria:\n\n* Any history or evidence of abnormal bleeding or coagulopathy; or evidence of prolonged or unexplained, clinically significant bleeding, or frequent unexplained bruising or thrombosis; or history of spontaneous bleeding;\n* Evidence of active or suspected cancer within 3 years prior to screening (non-melanoma skin cancer, localized prostate cancer treated with curative intent, or other in situ carcinoma that does not require systemic therapy and is considered cured for at least 1 years is allowed);\n* Acute febrile illness within 7 days prior to dose administration or evidence of active infection;\n* Any major surgery within 3 months prior to screening or plan to have any major surgery during the study;\n* History of clinically significant hypersensitivity, intolerance, or allergy to any oligonucleotide or GalNAc as determined by the investigator;\n* Fasting TG≥ 500 mg\u002FdL (5.6 mmol\u002FL) during screening;\n* Receipt of an investigational drug within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study;\n* Have previously completed or withdrawn from this study or any other study investigating SRSD216 and have previously received SRSD216.",true,"ALL","18 Years","70 Years",{"count":96,"type":97},84,"ESTIMATED","INTERVENTIONAL",[100,101],"PHASE1","PHASE2","This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or without ASCVD history.",[104],"Hyperlipoproteinemia (a)","2026-01-03",{"date":107,"type":108},"2026-01-06","ACTUAL",{"date":110,"type":108},"2025-04-07",{"date":112,"type":97},"2027-04",{"name":5,"class":6},1]